![1]()
News
Pneumonia risk soars in heart failure patients, especially HFpEF
April 19, 2021
An analysis of two large trials found that patients with heart failure have an elevated risk of pneumonia and related adverse cardiovascular events.
![1]()
News
Heart failure redefined with new classifications, staging
March 8, 2021
Heart failure terminology gets a landmark reno, with a new universal definition, revised stages of development and progression, and updated LVEF classifications.
![1]()
News
More from DAPA-HF: Dapagliflozin quickly reduces heart failure events
February 22, 2021
Secondary analysis of DAPA-HF showed dapagliflozin significantly cut CV deaths or worsening heart failure within 28 days on treatment.
![1]()
News
More Americans hospitalized, readmitted for heart failure
February 16, 2021
“We should be emphasizing the things we know work to reduce heart failure hospitalization, which is, number one, prevention.”
![1]()
News
Neprilysin, corin singled out for potential to guide heart failure therapy
January 28, 2021
Circulating neprilysin and corin concentrations, which correlate with outcomes, could possibly be assessed to guide heart failure therapy.
![1]()
News
Updated ACC decision pathway embraces new heart failure treatment strategies
January 11, 2021
The ACC’s updated decision pathway aims to close the substantial gap between current practice and unmet opportunities for inhibiting HFrEF progression.
News
Fracking sites tied to increased heart failure hospitalizations
December 10, 2020
The results were consistent and robust among more than 9,000 patients with heart failure in Pennsylvania, a state steeped in controversy over fracking.
![1]()
News
No link shown between thyroid dysfunction and heart failure
November 10, 2020
Analysis of nearly 5,000 English heart failure patients showed no significant link between thyroid dysfunction and survival.
![1]()
News
Updated heart failure measures add newer meds
November 2, 2020
Updated measures for heart failure account for newer medications, drug titration in cardiac resynchronization therapy, and patient-reported outcomes.
News
Entresto halves renal events in preserved EF heart failure patients
October 15, 2020
The PARAGON-HF trial of sacubitril/valsartan in patients with heart failure with preserved ejection fraction didn’t meet its primary outcome but significantly improved a secondary renal endpoint.